Aerosolized vancomycin therapy facilitating nursing home placement.
OBJECTIVE
To demonstrate a novel method of eliminating nasopharyngeal colonization by methicillin-resistant Staphylococcus aureus (MRSA) in a debilitated, hospitalized patient.


METHODS
Single-patient, nonblind, nonplacebo, case study.


METHODS
Community hospital, Brooklyn, NY.


METHODS
Hospitalized patient with recalcitrant nasopharyngeal MRSA colonization that could not be eliminated by conventional therapeutic interventions.


METHODS
Aerosolized vancomycin hydrochloride 120 mg q6h administered in room air via face mask together with vancomycin nasal drops, 2 drops to each nostril q6h.


METHODS
Elimination of MRSA from the nasopharynx of the patient.


RESULTS
Successful elimination of MRSA colonization after four days of therapy.


CONCLUSIONS
Aerosolized vancomycin in combination with vancomycin nasal drops is beneficial in eliminating nasopharyngeal colonization by MRSA. Clinical trials are warranted to confirm this clinical observation.
Gradon
J D
JD
Division of Infectious Diseases, Maimonides Medical Center, Brooklyn.
Wu
E H
EH
Lutwick
L I
LI
D000280:Administration, Inhalation; D000368:Aged; D000369:Aged, 80 and over; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D006764:Hospitals, Community; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D009305:Nasopharynx / Q000382:microbiology*; D009735:Nursing Homes; D010360:Patient Transfer; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000008:administration & dosage* / Q000627:therapeutic use
D014640:Vancomycin